Prognostic and predictive factors in high-grade gliomas. Experience at our institution

被引:0
|
作者
Alonso, Diana [1 ]
Matallanas, Manuel [1 ]
Riveros-Perez, Alba [2 ]
Perez-Payo, Maripaz [1 ]
Blanco, Sonia [1 ]
机构
[1] HUCA, Serv Oncol Radioterap, Oviedo, Spain
[2] Hosp Univ Doctor Negrin, Serv Oncol Radioterap, Las Palmas Gran Canaria, Las Palmas, Spain
来源
NEUROCIRUGIA | 2017年 / 28卷 / 06期
关键词
Glioma; Glioblastoma; Astrocytoma; GLIOBLASTOMA; MGMT; CLASSIFICATION; TEMOZOLOMIDE; METHYLATION; TUMORS;
D O I
10.1016/j.neucie.2017.07.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectiue: To describe and analyse predictive and prognostic factors of overall survival (OS) in high-grade gliomas at our institution. Material and method: All patients diagnosed with grade in (GIII) or grade iv (GIV) gliomas (excluding oligodendrogliomas, oligoastrocytomas or infratentorial gliomas) were prospectively included from November 2010 to August 2014. All were treated with surgery followed by adjuvant radiochemotherapy. The Kaplan-Meier method was used for the statistical analysis, considering a P value <.05 to be significant. Results: 89 patients were studied (18 GIII and 71 GIV). The average age was 60 years and 55% were men. The mean Karnofsky score was 80%. The most common location was the frontal lobe (38%). A total of 65% were partial resections. Complete chemotherapy was administered to 74% and complete RT to 83% of patients. Mean OS was 26.8 8.3 months for GIII and 12.5 1 month for GIV. 72 had died by the end of this study. A total of 40% of patients had MGMT methylation, 7% IDH1 mutation and 47% EGFR amplification. Statistically significant variables for OS were: GIII (P=.020), age <70 years (P=.040), <65 years (P=.013) and <60 years (P=.003), Kamofsky >70% (P=.029), complete radiotherapy (P=.000), complete resection (P=.001), MGMT methylation (P=.042), IDH1 mutation (P=.007) and EGFR non-amplification (P=.034). Additionally, GIII and GN subgroups were independently analysed. In GIII, the only significant biomarker for OS was IDH1 mutation, while in GN, MGMT methylation (P=.023) was significant. Age >70 years old was a significant factor in the GIII-subgroup (P=.040) but not for GIV (P=.166). Conclusions: Data are in line with previous studies, with the exception of age, which does not appear to be significant in GIV. 2017 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 50 条
  • [31] Molecular targeting with engineered interleukin 13 for imaging and treatment of human high-grade gliomas.
    Debinski, W
    Thompson, JP
    Gilbo, DM
    Slagle, B
    CLINICAL CANCER RESEARCH, 1999, 5 : 3804S - 3805S
  • [32] A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas.
    Clarke, Jennifer Leigh
    Molinaro, Annette M.
    DeSilva, Ashley A.
    Rabbitt, Jane E.
    Drummond, Daryl C.
    Chang, Susan Marina
    Butowski, Nicholas A.
    Prados, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Clinical Characteristics and Outcome of Children with Primarily Multicentric High-Grade Gliomas. A Retrospective Analysis
    Nussbaumer, G.
    Benesch, M.
    Gielen, G.
    Pietsch, T.
    Bison, B.
    Warmuth-Metz, M.
    Kortmann, R. D.
    Krause, M.
    Gurtner, K.
    Von Bueren, A. O.
    Kramm, C.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S143 - S143
  • [34] Novel gene expression patterns associated with progression and adverse outcome in high-grade gliomas.
    Chakravarti, A
    Mukherjee, N
    Mukherjee, S
    Zhai, G
    Robe, P
    Carroll, R
    Loeffler, JS
    Black, PM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 129S - 129S
  • [35] PROGNOSTIC FACTORS FOR WHO GRADE III GLIOMAS: A SINGLE INSTITUTION ANALYSIS
    Stevens, G. H. J.
    Ahluwalia, M.
    Hashemi, N.
    Peereboom, D.
    Barnett, G. H.
    NEURO-ONCOLOGY, 2012, 14 : 46 - 46
  • [36] Severe thrombocytopenia from temozolomide (TMZ) in newly diagnosed patients with high-grade gliomas.
    Gerber, David E.
    Grossman, Stuart A.
    CANCER RESEARCH, 2006, 66 (08)
  • [37] Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience
    Vasquez, Liliana
    Terrillo, Fanny
    Oscanoa, Monica
    Maza, Ivan
    Geronimo, Jenny
    Paredes, Gloria
    Maria Silva, Jose
    Sialer, Luis
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [38] Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas
    Wu, Jianing
    Al-Zahrani, Abdulrahman
    Beylerli, Ozal
    Sufianov, Rinat
    Talybov, Rustam
    Meshcheryakova, Svetlana
    Sufianova, Galina
    Gareev, Ilgiz
    Sufianov, Albert
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Gene expression profile as a prognostic factor in high-grade gliomas
    Czernicki, Tomasz
    Zegarska, Jolanta
    Paczek, Leszek
    Cukrowska, Bozena
    Grajkowska, Wieslawa
    Zajaczkowska, Agnieszka
    Brudzewsk, Kazimierz
    Ulaczyk, Jan
    Marchel, Andrzej
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (01) : 55 - 64
  • [40] The contribution of magnetic resonance spectroscopy to the classification of high grade gliomas.: The predictive value of macromolecules
    Martínez-Bisbal, MC
    Celda-Muñoz, B
    Martí-Bonmatí, L
    Ferrer-Ripollés, P
    Revert-Ventura, AJ
    Piquer-Belloch, J
    Mollá-Olmos, E
    de Moya, EAF
    Dosdá-Muñoz, R
    REVISTA DE NEUROLOGIA, 2002, 34 (04) : 309 - 313